Last Update 22 Jan 26

Fair value Decreased 8.09%

CLN: Revised Expectations And Legal Claims Will Shape Future Upside Potential

Analysts have reduced their price target for Clariant to CHF 7.80 from CHF 8.00, citing updated assumptions for fair value, discount rate, revenue growth, profit margins, and future P/E multiples.

Analyst Commentary

Recent research points to a more cautious stance on Clariant, with the price target trimmed to CHF 7.80 from CHF 8 and the rating held steady at Hold. That combination signals that analysts do not see a clear case for either strong upside or severe downside at current levels.

Bullish Takeaways

The maintained Hold rating suggests analysts still see the current share price as broadly aligned with their fair value work, rather than requiring a more negative stance.
The modest size of the price target reduction indicates that updated assumptions on discount rate, revenue growth, margins, or future P/E multiples did not materially change the overall equity story.
By keeping coverage and a neutral stance, bullish analysts appear to view Clariant as a name where execution improvements or more supportive end markets could help justify the revised valuation over time.

Bearish Takeaways

The cut in the price target to CHF 7.80 signals that analysts now see slightly less headroom for upside, even after revisiting their fair value framework.
Updated inputs for revenue growth, profit margins, and future P/E multiples point to more conservative expectations for the company’s ability to create value relative to prior assumptions.
The decision to keep a Hold rather than move to a more positive stance suggests analysts see limited near term catalysts for rerating, with the shares viewed more as fairly valued than mispriced.

What’s in the News

Clariant received two damages claims in the court of Munich from MOL Petrolkemia Zrt. and Slovnaft a.s. (MOL Group) in Hungary and from Braskem S.A. in Brazil. The claimed amounts are around €548 million and €402 million and are linked to alleged infringement of competition law in the ethylene purchasing market that was sanctioned by the European Commission in July 2020 (Key Developments).
The company has publicly rejected these damages claims and stated it will defend its position, pointing to economic evidence it says indicates the conduct of the parties did not produce any effect on the market (Key Developments).
Clariant AG confirmed earnings guidance for 2025, expecting local currency sales growth at the lower end of the 1% to 3% range (Key Developments).

Valuation Changes

Fair Value: reduced from 9.51 to 8.74, a modest step down in the analysts' intrinsic value estimate for Clariant.
Discount Rate: raised slightly from 5.84% to 5.93%, indicating a marginally higher required return in the updated model.
Revenue Growth: cut from 1.18% to 0.68%, reflecting more restrained expectations for top line expansion.
Profit Margin: lowered from 7.57% to 5.84%, pointing to a more conservative view on future profitability.
Future P/E: increased from 11.65x to 14.12x, signalling a higher assumed valuation multiple applied to future earnings.

Expansion in China and a focus on specialty, sustainable chemicals position Clariant to benefit from growing local demand and regulatory trends.
Ongoing digitalization, efficiency measures, and a premium product portfolio underpin cost savings, resilient margins, and long-term earnings growth despite slow sales growth.
Lingering macroeconomic weaknesses, competitive threats, and increased structural costs may constrain Clariant's revenue growth, margin strength, and long-term earnings stability.

Catalysts

About Clariant

Develops, manufactures, distributes, and sells specialty chemicals in Switzerland, Europe, the Middle East, Africa, the United States, and the Asia Pacific.What are the underlying business or industry changes driving this perspective?

The ramp-up of two new plants in China for Care Chemicals and Additives will significantly increase local production, aligning with rising local content requirements and sustainability preferences in Asia-Pacific. This positions Clariant to better capture demand from the expanding middle class and mitigate tariff risks, supporting multi-year revenue growth and margin stability.
Clariant's ongoing performance improvement and digitalization initiatives, such as the CLARITY platform in Catalysts and footprint optimization, are driving substantial cost savings and operational efficiencies. These measures are expected to deliver CHF 80 million annual savings by 2027 and aid in reaching a targeted 40% free cash flow conversion, boosting EBITDA margins and bottom line growth.
The company's increasing reliance on specialty and sustainable chemical solutions, illustrated by innovations like soil-release polymers and Lucas Meyer Cosmetics' premium segment growth, directly targets rising regulatory and consumer demand for environmentally friendly, high-value products. This supports premium pricing and recurring revenues, driving net margin resilience.
Clariant's higher-value, less commoditized portfolio, together with structural cost reductions and value-over-volume strategy, has consistently increased EBITDA margins (from 14.6% in 2023 to a guided 17-18% in 2025) despite modest organic sales growth, indicating a robust foundation for future earnings growth even in slow economic conditions.
Strategic capital redeployment into innovation-driven, regulation-compliant businesses (post-divestment of pigments and masterbatches) positions Clariant at the forefront of secular trends such as sustainability and the clean energy transition, opening new revenue streams in bio-based chemicals, EV batteries, and sustainable agriculture, which is likely to positively impact revenues and return on invested capital over the long-term.

Clariant Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Clariant's revenue will grow by 3.3% annually over the next 3 years.
Analysts assume that profit margins will increase from 2.8% today to 8.0% in 3 years time.
Analysts expect earnings to reach CHF 358.4 million (and earnings per share of CHF 1.08) by about September 2028, up from CHF 113.0 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting CHF410.5 million in earnings, and the most bearish expecting CHF206.2 million.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 12.0x on those 2028 earnings, down from 23.4x today. This future PE is lower than the current PE for the GB Chemicals industry at 26.5x.
Analysts expect the number of shares outstanding to decline by 0.11% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 5.79%, as per the Simply Wall St company report.

Clariant Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

Persistent weak industrial production outlook and ongoing macroeconomic uncertainties, particularly with slowing industrial and chemical production growth forecasts globally, may constrain Clariant's top-line revenue growth for multiple years, limiting overall earnings potential.
Increased exposure to China amid tariffs, overcapacity, and muted demand-despite ramping up local manufacturing-could keep volumes and prices under pressure in a key growth region, negatively impacting revenue stability and margin resilience.
Heavy restructuring and footprint rationalization, while supporting margins in the near term, may reduce business diversification and make Clariant more vulnerable to cyclical downturns or sector-specific shocks, ultimately risking revenue concentration and increasing earnings volatility.
Intensifying competition-both from Asian low-cost producers (which may drive global margin compression) and European peers willing to cut prices to sustain volumes-threatens Clariant's ability to maintain premium pricing and differentiated EBITDA margins long term.
Rising compliance costs related to decarbonization targets, ongoing legal risks such as the Ethylene litigation, and fixed cost increases from restructuring activities may collectively exert downward pressure on net income, free cash flow, and long-term earnings quality.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of CHF11.119 for Clariant based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of CHF16.0, and the most bearish reporting a price target of just CHF8.8.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be CHF4.5 billion, earnings will come to CHF358.4 million, and it would be trading on a PE ratio of 12.0x, assuming you use a discount rate of 5.8%.
Given the current share price of CHF8.06, the analyst price target of CHF11.12 is 27.5% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Clariant?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

Earnings Recovery Will Depend On Stabilization And Cost Improvements Amid Headwinds